KPL-404

KPL-404

Phase 1

Image of a Petri dish and pipette with sample

Rationale

CD40-CD40L interaction is an attractive target for blocking T-cell–mediated B-cell–driven autoimmunity and prevention of solid organ transplant rejection. External proof-of-concept for inhibition of this pathway has been previously established in patients with a broad range of autoimmune diseases, including rheumatoid arthritis, Sjögren’s syndrome, Graves’ disease, systemic lupus erythematosus and solid organ transplant.

Status: Phase 1

We reported preliminary data for our single-ascending-dose Phase 1 study in healthy volunteers for KPL-404 where all dose escalations occurred as per protocol with no dose limiting safety findings. All 6 subjects dosed with KPL-404 3 mg/kg IV showed full receptor occupancy through Day 29, which corresponded with complete suppression of the T-cell Dependent Antibody Response (TDAR) to KLH through Day 29. Consistent dose relatedness was shown in the lower dose level cohorts, including 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg IV and 1 mg/kg SC. Data collection for the higher dose level cohorts, 10 mg/kg intravenous and 5 mg/kg subcutaneous, is ongoing. The data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly administration. Kiniksa expects final data and safety follow-up from all cohorts in the first half of 2021.

Explore Our Pipeline

We are intent on developing an array of innovative therapies that answer the many and varied needs of patients.